The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD) cannabidiol acid (CBDA) cannabigerol (CBG) cannabigerolic acid (CBGA) cannabigerol propyl variant (CBGV) and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
